Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation-Reference-Cited by-同舟云学术

Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation

Published:2016-11 Issue: Volume:101 Page:11-15
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Tanizaki Junko,Banno Eri,Togashi Yosuke,Hayashi Hidetoshi,Sakai Kazuko,Takeda Masayuki,Kaneda Hiroyasu,Nishio Kazuto,Nakagawa Kazuhiko

Funder

Grant-in-Aid

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference18 articles.

1. EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-Generation TKIs;Kobayashi;Clin. Cancer Res.,2015

2. Rociletinib in EGFR-mutated non-small-cell lung cancer;Sequist;N. Engl. J. Med.,2015

3. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer;Janne;N. Engl. J. Med.,2015

4. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial;Park;Lancet Oncol.,2016

5. ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: preliminary results of first-in-human phase I study in Japan;Goto;ASCO Meeting Abstr.,2015

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutually exclusive driver mutations identifies 2 separate primaries in a collision tumor initially interpreted as a solitary lung adenocarcinoma with tumor heterogeneity;Respiratory Medicine Case Reports;2024

2. Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review;Clinical Lung Cancer;2021-05

3. Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non–Small-Cell Lung Cancer;Clinical Lung Cancer;2019-09

4. Challenges of Providing Concordant Interpretation of Somatic Variants in Non-Small Cell Lung Cancer: A Multicenter Study;Journal of Cancer;2019

5. Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations;Lung Cancer;2018-06